Abstract
Down syndrome (DS), the most common genetic cause of intellectual disability, is caused by the trisomy of chromosome 21. MNB/DYRK1A (Minibrain/dual specificity tyrosine phosphorylation-regulated kinase 1A) has possibly been the most extensively studied chromosome 21 gene during the last decade due to the remarkable correlation of its functions in the brain with important DS neuropathologies, such as neuronal deficits, dendrite atrophy, spine dysgenesis, precocious Alzheimer’s-like neurodegeneration, and cognitive deficits. MNB/DYRK1A has become an attractive drug target because increasing evidence suggests that its overexpression may induce DS-like neurobiological alterations, and several small-molecule inhibitors of its protein kinase activity are available. Here, we summarize the functional complexity of MNB/DYRK1A from a DS-research perspective, paying particular attention to the capacity of different MNB/DYRK1A inhibitors to reverse the neurobiological alterations caused by the increased activity of MNB/DYRK1A in experimental models. Finally, we discuss the advantages and drawbacks of possible MNB/DYRK1A-based therapeutic strategies that result from the functional, molecular, and pharmacological complexity of MNB/DYRK1A.
Keywords: Down syndrome, minibrain, neuropathologies, cognitive deficit, trisomy 21, harmine, epigallocatechin-gallate.
CNS & Neurological Disorders - Drug Targets
Title:DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies
Volume: 13 Issue: 1
Author(s): Walter Becker, Ulf Soppa and Francisco J. Tejedor
Affiliation:
Keywords: Down syndrome, minibrain, neuropathologies, cognitive deficit, trisomy 21, harmine, epigallocatechin-gallate.
Abstract: Down syndrome (DS), the most common genetic cause of intellectual disability, is caused by the trisomy of chromosome 21. MNB/DYRK1A (Minibrain/dual specificity tyrosine phosphorylation-regulated kinase 1A) has possibly been the most extensively studied chromosome 21 gene during the last decade due to the remarkable correlation of its functions in the brain with important DS neuropathologies, such as neuronal deficits, dendrite atrophy, spine dysgenesis, precocious Alzheimer’s-like neurodegeneration, and cognitive deficits. MNB/DYRK1A has become an attractive drug target because increasing evidence suggests that its overexpression may induce DS-like neurobiological alterations, and several small-molecule inhibitors of its protein kinase activity are available. Here, we summarize the functional complexity of MNB/DYRK1A from a DS-research perspective, paying particular attention to the capacity of different MNB/DYRK1A inhibitors to reverse the neurobiological alterations caused by the increased activity of MNB/DYRK1A in experimental models. Finally, we discuss the advantages and drawbacks of possible MNB/DYRK1A-based therapeutic strategies that result from the functional, molecular, and pharmacological complexity of MNB/DYRK1A.
Export Options
About this article
Cite this article as:
Becker Walter, Soppa Ulf and Tejedor J. Francisco, DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies, CNS & Neurological Disorders - Drug Targets 2014; 13 (1) . https://dx.doi.org/10.2174/18715273113126660186
DOI https://dx.doi.org/10.2174/18715273113126660186 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Hypertensive Left Ventricular Hypertrophy
Current Pharmaceutical Design Incretin-Based Therapy of Type 2 Diabetes Mellitus
Current Protein & Peptide Science Enhanced Selectivity Screening of GPCR Ligands Using a Label-Free Cell Based Assay Technology
Combinatorial Chemistry & High Throughput Screening A Case of 2:1 Atrio-Ventricular Block- Unraveled by Exercise Testing
New Emirates Medical Journal Novel Targets of Metformin in Cardioprotection: Beyond the Effects Mediated by AMPK
Current Pharmaceutical Design Semi-Quantitative Ultrasonographic Evaluation of NAFLD
Current Pharmaceutical Design Lipid Management and Peripheral Arterial Disease
Current Drug Targets Inflammation Markers in Essential Hypertension
Medicinal Chemistry The NPC1L1 Inhibitor Ezetimibe in the Treatment of the Dyslipidemia in Patients Affected by the Metabolic Syndrome: Evidences and Perspectives
Current Enzyme Inhibition Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Massively Parallel Screening of the Receptorome
Combinatorial Chemistry & High Throughput Screening Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery <i>Thespesia populnea</i>: An Ethnomedicinal, Phytochemical and Pharmacological Review
The Natural Products Journal Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Active Phytochemicals from Chinese Herbs as Therapeutic Agents for the Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacogenetics in Cardiovascular Antithrombotic Therapy
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology Vascular Risk Factors, Vascular Diseases, and Imaging Findings in a Hospital-based Cohort of Mild Cognitive Impairment Types
Current Alzheimer Research Extra-Hematopoietic Effects of Erythropoietin
Cardiovascular & Hematological Disorders-Drug Targets Advanced In Silico Approaches for Drug Discovery: Mining Information from Multiple Biological and Chemical Data Through mtk- QSBER and pt-QSPR Strategies
Current Medicinal Chemistry